Bank of New York Mellon Corp Takes Position in Regulus Therapeutics Inc. (NASDAQ:RGLS)

Bank of New York Mellon Corp bought a new position in Regulus Therapeutics Inc. (NASDAQ:RGLS) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 197,193 shares of the biopharmaceutical company’s stock, valued at approximately $352,000. Bank of New York Mellon Corp owned about 0.30% of Regulus Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the stock. Opaleye Management Inc. bought a new stake in shares of Regulus Therapeutics during the 1st quarter worth $490,000. Vanguard Group Inc. lifted its position in Regulus Therapeutics by 158.4% during the 1st quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock worth $2,132,000 after acquiring an additional 453,784 shares during the last quarter. CVI Holdings LLC bought a new stake in shares of Regulus Therapeutics in the 1st quarter worth approximately $4,050,000. RA Capital Management L.P. acquired a new stake in shares of Regulus Therapeutics during the 1st quarter worth approximately $18,000,000. Finally, NEA Management Company LLC bought a new stake in shares of Regulus Therapeutics during the first quarter valued at approximately $18,627,000. Institutional investors own 92.38% of the company’s stock.

Regulus Therapeutics Stock Up 2.6 %

Shares of Regulus Therapeutics stock opened at $1.59 on Thursday. Regulus Therapeutics Inc. has a 12-month low of $1.08 and a 12-month high of $3.79. The stock has a market capitalization of $104.09 million, a P/E ratio of -1.09 and a beta of 1.63. The company has a 50-day simple moving average of $1.64 and a 200 day simple moving average of $2.05.

Regulus Therapeutics (NASDAQ:RGLS) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.17). On average, equities analysts anticipate that Regulus Therapeutics Inc. will post -0.8 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on RGLS. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Regulus Therapeutics in a research report on Friday, August 9th. Canaccord Genuity Group raised their price objective on shares of Regulus Therapeutics from $11.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, June 25th. StockNews.com raised shares of Regulus Therapeutics to a “sell” rating in a research note on Tuesday, September 17th. Finally, Oppenheimer restated an “outperform” rating and set a $7.00 price target on shares of Regulus Therapeutics in a research note on Wednesday, August 14th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $10.80.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.